Clearovac

Macrogol

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clearovac

Property	Description
Active ingredient	Macrogol (Polyethylene Glycol or PEG)
Form	Powder for oral solution
Pharmacological class	Osmotic Laxative
General Use	Relief of difficult or infrequent bowel movements
Origin	Synthetic Polymer

Clearovac is a pharmaceutical product whose defining active ingredient is Macrogol, the non-proprietary name for Polyethylene Glycol or PEG. Macrogol is a synthetic, high-molecular-weight polymer that is structurally and functionally classified as an Osmotic Laxative. Its core identity is that of a physical agent, acting locally within the gastrointestinal tract and remaining biologically inert as it is negligibly absorbed into the systemic circulation.

What Type of Medicine is Clearovac?

Clearovac is designated an Osmotic Laxative, a pharmacological classification reflecting its non-stimulant mechanism of action. The substance’s synthetic origin ensures it is not subject to enzymatic or bacterial degradation in the intestine, a characteristic that often differentiates it from fermentable agents. This non-fermentable nature is recognized as contributing to potentially better gastrointestinal tolerance in comparison to some other osmotic laxatives. Macrogol provides a method of managing these issues, and it is considered an established approach for restoring comfortable bowel function.

Clearovac Composition and Pharmaceutical Form

The medication is typically supplied as a powder for oral solution, designed for consumption via the oral route. The formulation contains Macrogol 3350 or Macrogol 4000 as the primary component. Importantly, the powder often incorporates necessary electrolytes—such as sodium and potassium salts—to create an isosmotic solution once prepared. This design is intended to prevent the solution from disrupting the body's natural balance of water and salts. This balanced composition is associated with favorable patient tolerability profiles. This specific formulation design is intended to help patients maintain normal fluid and electrolyte levels while using the product. This electrolyte-balanced powder form is common across major formulations, providing an established model for efficacy and patient safety.

What is the General Purpose of Macrogol-Based Therapy?

The general purpose of Clearovac is to facilitate easier and more regular bowel movement through sustained hydration of the faecal mass. The medication’s osmotic action causes it to draw and retain water molecules within the lumen of the colon. This process directly increases the stool's volume and significantly enhances its softness, enabling the gentle, predictable passage of material. The overall benefit is the relief of discomfort associated with hard, dry stool and inefficient intestinal transit, serving as a reliable method for restoring normal function in a typical use scenario.

Regulatory References

What side effects are possible with Clearovac?

Possible Side Effects and Safety Information

The official safety documents for Macrogol, the active ingredient in Clearovac, classify its adverse reactions primarily around localized effects in the digestive system and the rare potential for systemic allergic responses. The following classifications reflect the frequency and organ systems as documented by governmental regulatory authorities.

Adverse Reaction Scope

Category	Official Regulatory Classification/Entity
Key Adverse Reaction Categories	Gastrointestinal disturbances and Hypersensitivity reactions.
Frequency Classification	Common (up to 1 in 10): Diarrhoea, Abdominal Pain, Nausea, Abdominal Distension (Bloating), Vomiting. Uncommon: Anal discomfort, Mild Hypersensitivity Reactions. Rare: Severe Hypersensitivity Reactions.
System-Organ Classes Involved	Gastrointestinal Disorders (Primary), Immune System Disorders, Nervous System Disorders (linked to electrolyte imbalance in high-risk patients), Cardiac Disorders (linked to electrolyte imbalance in high-risk patients).
Serious Adverse Reactions	Anaphylactic Shock, Angioedema (swelling of the face or throat), Seizures, and Cardiac Arrhythmias (the latter two associated with underlying fluid/electrolyte abnormalities due to excessive loss).

Safety Considerations and Restrictions

Safety labels define specific limitations where the medicine should not be used (Contraindications). This medication is strictly prohibited in cases of known or suspected Gastrointestinal (GI) obstruction, Bowel perforation, Ileus, or severe inflammatory conditions such as Toxic Colitis or Toxic Megacolon.

The safety profile notes that gastrointestinal effects, such as diarrhoea and abdominal pain, are documented as being more likely at the start of treatment or when the dose is exceeded. Specific caution is noted for patients with Renal Impairment due to an increased risk of fluid and electrolyte abnormalities.

This regulatory structure establishes that while GI effects are common, the most serious risks are rare systemic reactions or complications arising from its use in individuals with existing severe GI obstructions or imbalances.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Clearovac overdose centers on the consequences of the product's excessive osmotic effect. Documented manifestations of overdose include severe diarrhea, abdominal pain, and excessive fluid loss leading to clinical signs of dehydration and electrolyte imbalance (e.g., potassium and sodium abnormalities).

The primary severe outcomes associated with this profile are profound fluid and electrolyte disturbances. Regulators document that these imbalances carry the risk of serious adverse reactions, including potential cardiac arrhythmias and seizures. Susceptibility to severe outcomes is noted for elderly patients and individuals with compromised renal function or heart failure.

Regulator-Mandated Emergency Actions

In the event of suspected overdose or the onset of severe symptoms, official regulatory guidance mandates two immediate actions: immediate discontinuation of the product and the requirement to seek immediate medical attention or contact a Poison Control Center right away. The official prescribing information states that no specific antidote is known for Macrogol overdose.

Therefore, management is exclusively symptomatic and supportive treatment, with the critical intervention being the intensive correction of fluid and electrolyte abnormalities. Hospital monitoring of serum electrolytes and fluid status may be required.

Therapeutic Uses of Clearovac

What Clearovac Treats: Main Uses and Benefits

Quick Facts
Indicated for: Management of specific chronic conditions
Therapeutic Role: May help address symptoms associated with systemic discomfort
Primary Use: Used to assist in maintaining function in affected areas

Clearovac is a medication indicated for the management of certain chronic conditions that present with systemic discomfort and functional decline. The treatment is used to address key symptoms, which may include localized swelling and persistent stiffness in affected tissue.

Therapeutically, Clearovac may assist in supporting the body’s ability to manage its response to the condition. It is not intended as a definitive cure but is utilized within a broader treatment regimen to promote stability and comfort. Consistent use, as determined by a healthcare provider, may help patients maintain function and improve their day-to-day quality of life over time.

For comprehensive information regarding the authorized therapeutic domains, patients and caregivers are encouraged to consult their physician. The medication is part of protocols designed to provide symptomatic relief, allowing individuals to better manage the impact of the condition.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Clearovac

The eligibility for Clearovac, a Macrogol-based product, is determined by age, pre-existing gastrointestinal conditions, and specific comorbidities, as defined in official regulatory documents.

Eligibility Scope
Populations for whom use is allowed (as stated in label): Adults and adolescents over 12 years old. Use is generally permitted for older adults.
Pregnancy and Lactation: Use is permitted and considered compatible due to the active ingredient's negligible systemic absorption.
Organ Function: No dose adjustment is typically necessary for patients with renal or hepatic impairment, based on the drug's limited absorption.

Contraindications and Restrictions
Populations for whom use is contraindicated: Patients with known hypersensitivity to Macrogol, intestinal obstruction (ileus), intestinal perforation or risk of perforation, or severe inflammatory bowel diseases such as active Crohn’s disease or ulcerative colitis.
Age-Related Non-Eligibility: The adult formulation is not recommended for children below 12 years of age. Dedicated paediatric products are required for this group.
Conditional Use: Caution is advised for patients with severely impaired cardiovascular function during high-dose regimens, and for those with an impaired gag reflex due to aspiration risk.

Connection to the overall eligibility profile: Official regulatory documents strictly prohibit the use of this medicine in the presence of severe acute intestinal pathologies. Eligibility is otherwise broadly established for adults, including pregnant and breastfeeding women, due to the regulatory classification of Macrogol as being negligibly absorbed by the body.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Clearovac are primarily categorized by the potential clinical significance of combining it with other substances or in the presence of certain medical conditions. These classifications, based on official regulatory data, are used to guide combination decisions and monitoring.

Classification	Severity Definition
Major	Highly clinically significant; combinations must be avoided as the risk outweighs the benefit.
Moderate	Moderately clinically significant; combinations should usually be avoided and used only under special circumstances.
Minor	Minimally clinically significant; minimize risk by considering an alternative or instituting a monitoring plan.

Disease Interactions

Use of this product is contraindicated or requires caution in the presence of specific gastrointestinal disorders. The official documentation identifies these as significant interaction contexts:

Intestinal Obstruction Disorders: Use is generally contraindicated.
Gastrointestinal (GI) Obstruction or Perforation: Use is generally contraindicated.
Inflammatory Bowel Disease (IBD): Use requires caution and monitoring, as increased gut activity may worsen the condition.

While hundreds of potential drug interactions are categorized as Moderate or Minor, the official labeling does not specifically list the names of interacting medicinal products, nor does it typically detail the pharmacokinetic mechanisms (e.g., enzyme inhibition or induction) underlying these interactions. Patients should inform their healthcare provider of all prescription and non-prescription medicines, vitamins, and supplements being taken.

Mechanism of Action

Osmotic Water Sequestration and Faecal Hydration

Clearovac's mechanism is fundamentally physical and biologically inert, meaning the core ingredient, Macrogol, does not engage with any receptors, enzymes, or nerve endings. Instead, it acts as a highly hydrophilic polymer that binds and sequesters water molecules within the lumen of the colon via osmotic action. This retained fluid increases the hydration level and volume of the faecal mass. This high hydration level reduces the physical resistance of the faecal matter to movement.

Indirect Modulation of Colonic Motility

The resultant increase in faecal volume and softness serves as a mechanical stimulus for the intestinal wall. The resulting physical distension of the colon triggers the body's natural neuromuscular reflexes, leading to an increase in propulsive peristalsis (motility). This mechanism, secondary to the volume effect, results in the organized forward transport of the softened faecal matter.

Isosmotic Design and Systemic Fluid Homeostasis

The formulation includes complementary electrolytes that maintain the solution's isosmolarity relative to the body's plasma. This mechanical design ensures that the potent osmotic action in the intestine is localized, preventing a net disruptive shift of water and essential salts across the intestinal barrier and thereby maintaining systemic fluid and electrolyte homeostasis.

Dosage and Administration Information

How to Use Clearovac: Official Administration Guidelines

Clearovac is an osmotic agent administered via the oral route as a powder for solution. The product must be correctly prepared by fully dissolving the measured dose in a specific volume of liquid, typically between 120 to 240 milliliters of water or another compatible beverage, just before consumption.

The standard adult regimen for general use involves taking the dose, often 17 grams, once daily. The administration timing is flexible, as it is generally independent of food consumption. For specific, short-term management of conditions like faecal impaction, standard guidelines include a higher, divided dose schedule that must not exceed a duration of three days.

For routine use, the duration of therapy is often limited to 7 to 14 days for initial management. There are different protocols for pediatric patients, with precise lower-dose regimens and age restrictions. Importantly, due to the drug's minimal systemic absorption, no dosage adjustment is required for individuals with renal or hepatic impairment. If a dose is missed, patients should continue with the next scheduled dose without taking an extra amount.

Recent Clinical Evidence

Research evidence / Overview of studies for Clearovac

Evidence for use in Chronic Functional Constipation

Macrogol was studied for chronic functional constipation in a large body of research, which includes numerous Randomized Controlled Trials (RCTs). In these trials, Macrogol was compared against a placebo (an inactive substance) or against other widely used osmotic agents, such as Lactulose. These studies explored outcomes related to perceived discomfort and functional balance by monitoring specific measures: primarily, the frequency of bowel movements per week and objective changes in stool characteristics. The research was observed in diverse groups, including adults, children, and older adults.

Findings describe patterns observed in the studies where studies reported measurements of increased bowel movement frequency and softer stool consistency compared to placebo. Data show patterns related to these reported changes in measured outcomes across both adult and pediatric populations with functional constipation.

Trial Design and Comparator Studies

The research examined how Macrogol was evaluated in studies against established therapies. Studies explored whether findings describe similar patterns observed in the studies when comparing Macrogol to other osmotic laxatives like Lactulose. This type of research contributes to the broader evidence landscape by providing context on how Macrogol was observed in different therapeutic settings.

Evidence for use in Managing Faecal Impaction

Research examined the use of Macrogol in conditions associated with acute or disruptive episodes, specifically faecal impaction. Studies monitored the acute effect, where findings describe patterns observed in the studies related to successful clearance of the faecal mass. These trials reported measurements related to successful resolution of faecal impaction. Data for certain groups, particularly adults with impaction, remain limited, as the existing evidence is heavily concentrated on the pediatric population.

What is Still Uncertain About the Evidence Base for Clearovac

Evidence highlights what is known — and what is still uncertain regarding Macrogol. Research limitations include the fact that follow-up durations were limited in many initial comparative studies. Subgroup findings are uncertain for certain specific symptoms, such as the consistent relief of global abdominal pain in patients with IBS-C, despite the clear functional changes reported in studies. The long-term effects are not fully established across all metrics, and data for certain groups and rare patient profiles remain insufficient, indicating that research is ongoing to broaden this understanding.

Frequently Asked Questions (FAQ)

Common questions about Clearovac (FAQ)

Q: Do I need to take Clearovac every day?

The standard regimen described in official product information for relief of occasional constipation is to take the product once daily. Use of the product for routine management should typically not exceed 7 days. Patients are generally advised to follow the duration of use determined by a healthcare provider.

Q: Is it normal to have mild stomach upset when starting Clearovac?

Official safety documents indicate that gastrointestinal effects are common, and these may include mild stomach upset, such as abdominal pain, nausea, and bloating. These reactions are documented as being more likely to occur when you first begin treatment with Clearovac.

Q: What should I do if a common side effect of Clearovac doesn't go away?

Official labeling states that consultation with a healthcare provider is warranted if gastrointestinal symptoms, such as nausea, bloating, or abdominal pain, worsen or persist. Consultation is also warranted if the product is needed for longer than one week for occasional constipation.

Q: Does Clearovac affect birth control pills or devices?

Official documents state that the primary ingredient in Clearovac has the potential to impact the absorption of other orally administered medicines taken concurrently. It is noted in official information that patients should inform a healthcare professional about all prescription medicines, including contraceptives, that they are taking.

Q: Are the reported side effects of Clearovac common or rare?

Regulatory safety documents classify adverse reactions by frequency. Adverse reactions such as diarrhoea and abdominal pain are classified as common in regulatory documents. More severe systemic reactions, such as anaphylactic shock (a severe allergic reaction), are classified as rare.

Q: Is Clearovac used for treating conditions other than the primary one listed?

The primary purpose defined in the majority of official labeling for Clearovac is the relief of occasional constipation (irregularity). This use is achieved by softening the stool and increasing bowel movement frequency.

Q: When should I expect to notice any effect after starting Clearovac?

Official information indicates that a change in bowel function is generally produced within 1 to 3 days (or 48 to 96 hours) after initiating the use of the product.

Q: Can I take Clearovac if I am also taking over-the-counter pain relievers?

Macrogol may affect the absorption of other oral medications taken at the same time. Official documents state that patients should inform a healthcare provider or pharmacist about all prescription and non-prescription medicines being taken before starting Clearovac.

Q: Does Clearovac interact with any common vitamins or supplements?

Due to the potential for the active ingredient to reduce the absorption of oral medicines taken concurrently, official documents state that patients should inform a healthcare provider of all prescription and non-prescription medicines, vitamins, and supplements being taken.

Q: Is it safe to consume alcohol while taking Clearovac?

Official labeling includes a specific caution regarding an alcohol/food interaction with the product. Regulatory information indicates that consultation with a healthcare provider is warranted when considering any combination.

Q: Do any foods need to be avoided when using Clearovac?

The dry powder is designed to be dissolved in various beverages, including water, juice, soda, coffee, or tea. However, regulatory documents specify that the product should not be combined with starch-based thickeners used for difficulty swallowing.

Q: What is the general difference between the tablet and capsule forms of Clearovac?

The form of the product described in the majority of official regulatory documents is a powder for oral solution. These documents do not generally describe the availability of tablet or capsule forms for this specific product concept.

Q: Is Clearovac available as a generic medicine?

The active ingredient, Polyethylene Glycol 3350 (Macrogol), is available in the United States and other markets under both a branded product name and multiple generic or authorized non-prescription labels.

Q: Does Clearovac have any known interactions with herbal teas?

As with any oral medicine, there is a potential for Macrogol to reduce the absorption of other substances taken at the same time. Official documents state that patients should inform a healthcare provider of all prescription and non-prescription medicines, including any herbal teas, being taken.

Q: Is it necessary to take Clearovac with food?

Official prescribing information states that administration is generally independent of food consumption. The dose may be dissolved and taken in any 4 to 8 ounces of various compatible beverages.

Q: How quickly is Clearovac removed from the body?

The product works locally in the digestive system and is minimally absorbed. For the small amount that does enter the bloodstream, pharmacokinetic studies indicate the half-life—the time for half the substance to be eliminated—is described as approximately 4 to 8 hours in subjects with normal kidney function.

Q: Do I need a special prescription for Clearovac?

The regulatory status of Macrogol products, as an Over-the-Counter (OTC) or Prescription (Rx) medicine, can vary. The status depends on the specific formulation, the country, and local regulatory guidelines.

Q: Does the time of day matter when taking Clearovac?

Official guidelines describe administration timing as flexible. The product is to be taken once daily and is generally independent of food consumption, allowing flexibility in the time of day it is taken.

Q: Can Clearovac be taken at the same time as cold or flu medicine?

Due to the potential for the active ingredient to reduce the absorption of oral medicines taken concurrently, official documents state that patients should inform a healthcare provider of all prescription and non-prescription medicines, including cold or flu treatments, being taken.

Q: Can Clearovac affect my blood sugar levels?

Regulatory information indicates that Macrogol has no demonstrated effect on the active absorption or secretion of glucose (sugar) in the body. Furthermore, the formulation is typically described as being sugar-free.

Q: Is Clearovac a new drug or has it been used for many years?

Official European and other regulatory agencies confirm Macrogol (Polyethylene Glycol) is a well-established and accepted product. It is described as a well-established and accepted product for use in managing bowel function.

How should Clearovac be stored and disposed of?

How to Store and Dispose of Clearovac

Storage requirements for Clearovac, an osmotic laxative powder, differ between the dry powder and the prepared solution.

Storage Conditions

Product Form	Storage Requirement
Dry Powder	Store in the original container, not above 25 C. Keep out of the sight and reach of children.
Reconstituted Solution	Store covered in a refrigerator (between 2 C and 8 C).